Canadian DIN & Molecule SearchMolecules A–ZDrug ShortagesResourcesHealth Canada WeeklyRequest a Quote

NEOSTIGMINE OMEGA 0.5 MG — DIN 02230593

NEOSTIGMINE METHYLSULFATE : 0.5 MG · OMEGA LABORATORIES LIMITED · LIQUID · wholesale supply in Canada

Health Canada status: MARKETED

What is NEOSTIGMINE OMEGA?

NEOSTIGMINE OMEGA 0.5 MG contains NEOSTIGMINE METHYLSULFATE : 0.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02230593, held by OMEGA LABORATORIES LIMITED, supplied as LIQUID for INTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Jul-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.

What is NEOSTIGMINE OMEGA used for?

Prophylaxis and treatment of postoperative intestinal atony, urinary retention; in serious cases of myasthenia gravis: to neutralize effect of curare in surgical anesthesia and shock therapy.

Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.

How much does Neostigmine cost around the world?

Neostigmine is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.

What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Morocco publishes a PPV (public price); South Africa publishes a single exit price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.

MarketPrice basis published thereBrandsPacks listedRange
United Kingdomhospital22GBP███.██
South Africasingle exit price12ZAR███.██
Greeceproducer price (ex-factory)11EUR███.██
MoroccoPPV (public price)11MAD███.██

6 pack listings across 5 brand entries and 4 price bases, refreshed 05 Sep 2026. Ranges span every Neostigmine pack in that market, so a high figure is usually a larger pack rather than the same product.

Figures are held for the Nexara team. Cross-market prices are published on incompatible bases and are not an offer, a landed cost, or a guide to what any buyer can obtain. Nexara publishes which markets list the product and on what basis; the numbers stay internal.

Team sign-in

Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.

Ask Nexara for a landed Canadian price

Is there a generic Neostigmine in Canada, and who makes it?

Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.

11 holders have a Canadian DIN containing Neostigmine, across 26 DINs, of which 6 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.

Market authorization holderDINsMarketedBrand namesPosition
OMEGA LABORATORIES LIMITED33NEOSTIGMINE OMEGASourceable in Canada
MARCAN PHARMACEUTICALS INC22NEOSTIGMINE METHYLSULFATE INJECTION USPSourceable in Canada
JAMP PHARMA CORPORATION11NEOSTIGMINE METHYLSULFATE INJECTION, USPSourceable in Canada
SANDOZ CANADA INCORPORATED50NEOSTIGMINE METHYLSULFATE INJECTION SDZ, NEOSTIGMINE METHYLSULFATE INJECTION USPNo marketed DIN
ICN CANADA LTD.30PROSTIGMIN INJ 1:1000 USP, PROSTIGMIN INJ 1:2000 USP, PROSTIGMIN INJ 1:400 USPNo marketed DIN
JUNO PHARMACEUTICALS CORP.30NEOSTIGMINE METHYLSULFATE INJECTION, USPNo marketed DIN
DAVID BULL LABORATORIES (PTY) LTD.20NEOSTIGMINE METHYLSULFATE INJ 0.5MG/ML USP, NEOSTIGMINE METHYLSULFATE INJ 1MG/ML USPNo marketed DIN
FRESENIUS KABI CANADA LTD20NEOSTIGMINE METHYLSULFATE INJECTIONNo marketed DIN
PHARMASCIENCE INC20PMS-NEOSTIGMINE METHYLSULFATE INJ 0.5MG/ML, PMS-NEOSTIGMINE METHYLSULFATE INJ 1MG/MLNo marketed DIN
STERIMAX INC20NEOSTIGMINE METHYLSULFATE INJECTION USPNo marketed DIN
BAUSCH HEALTH, CANADA INC.10PROSTIGMINNo marketed DIN

Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.

How is it supplied and stored?

Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.

Strength on the label0.5 MG
Dosage formLIQUID
RouteINTRAMUSCULAR ; SUBCUTANEOUS ; INTRAVENOUS
Pack configuration (monograph)0.5 mg/mL: multidose vials of 1 mL and 10 mL, boxes of 10. 1 mg/mL: multidose vials of 10 mL, boxes of 10. 2.5 mg/mL: multidose vials of 5 mL, boxes of 10.
StorageStore between 15 and 30°C. Protect from light. Multiple use. Discard 28 days after initial use.

Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.

Substance and classification

Active substanceNeostigmine
ATC codeN07AA01
AHFS class12:04.00
Biosimilar biologicNo

Confirm the pack and get a price

Health Canada record and identifiers

The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.

DIN (8-digit, as used in ordering)02230593
DIN (unpadded, as printed on some documents)2230593
Brand nameNEOSTIGMINE OMEGA
Generic / active ingredientNEOSTIGMINE METHYLSULFATE : 0.5 MG
Market authorization holderOMEGA LABORATORIES LIMITED
Health Canada schedulePrescription
ATC codeN07AA01
ATC anatomical main groupN — Nervous system
ATC therapeutic subgroupN07AA
Current statusMARKETED
Status date23-Jul-1999
Original market date1999-05-28 00:00:00
Status sourceLive Health Canada DPD sync

Verify on the primary sources

Health Canada DPD record Approved product monograph (PDF)

What can be used instead?

Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.

1 · Same molecule, other Canadian presentations

6 of 26 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.

ProductStrengthFormHolderHealth Canada statusDIN
NEOSTIGMINE METHYLSULFATE INJECTION USP1 MGSOLUTIONMARCAN PHARMACEUTICALS INCMARKETED02475499
NEOSTIGMINE METHYLSULFATE INJECTION USP0.5 MGSOLUTIONMARCAN PHARMACEUTICALS INCMARKETED02475480
NEOSTIGMINE METHYLSULFATE INJECTION, USP0.5 MGSOLUTIONJAMP PHARMA CORPORATIONMARKETED02537516
NEOSTIGMINE OMEGA2.5 MGSOLUTIONOMEGA LABORATORIES LIMITEDMARKETED02387166
NEOSTIGMINE OMEGA1 MGLIQUIDOMEGA LABORATORIES LIMITEDMARKETED02230592
NEOSTIGMINE METHYLSULFATE INJ 0.5MG/ML USP.5 MGLIQUIDDAVID BULL LABORATORIES (PTY) LTD.CANCELLED POST MARKET01904183
NEOSTIGMINE METHYLSULFATE INJ 1MG/ML USP1 MGLIQUIDDAVID BULL LABORATORIES (PTY) LTD.CANCELLED POST MARKET01914588
NEOSTIGMINE METHYLSULFATE INJECTION0.5 MGLIQUIDFRESENIUS KABI CANADA LTDCANCELLED PRE MARKET02243104
NEOSTIGMINE METHYLSULFATE INJECTION1 MGLIQUIDFRESENIUS KABI CANADA LTDCANCELLED PRE MARKET02243103
NEOSTIGMINE METHYLSULFATE INJECTION SDZ2.5 MGSOLUTIONSANDOZ CANADA INCORPORATEDCANCELLED PRE MARKET02385228

2 · Same class — other molecules in ATC N07AA

MoleculeCanadian brandsDINsMarketedSourceable
NeostigmineNEOSTIGMINE METHYLSULFATE INJ 0.5MG/ML USP · NEOSTIGMINE METHYLSULFATE INJ 1MG/ML USP · NEOSTIGMINE METHYLSULFATE INJECTION · NEOSTIGMINE METHYLSULFATE INJECTION SDZ · +9 more266Yes
PyridostigmineJAMP PYRIDOSTIGMINE BROMIDE · MESTINON · MESTINON-SR · REGONOL INJ 5MG/ML · +1 more54Yes

A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.

3 · Adjacent classes in ATC N07A

ATC subgroupMoleculesDINsMarketed
N07AXPilocarpine53
N07ABBethanechol · Carbachol172

Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.

What else is NEOSTIGMINE OMEGA called?

The same molecule, Neostigmine, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:

NameScriptRegistered in
Micro-NeostigmineLatinSouth Africa
PROSTIGMINELatinMorocco

Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.

How can I get it?

Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.

Request a quote for NEOSTIGMINE OMEGA

Ordering questions

Who can buy this from Nexara?

Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.

Is there a minimum order?

Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.

What is the lead time?

Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.

Why is there no price on this page?

Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.

Can Nexara supply this for a clinical trial?

Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.

Sources and disclaimer

Product data sourced from the Health Canada Drug Product Database and the approved product monograph (PDF). Health Canada status reconciled against the live DPD sync. Last reviewed 10 Sep 2026.

Nothing on this page is medical advice. Nexara Health is a licensed wholesale distributor and supplies licensed entities only; consumer orders are routed to a partner pharmacy. Alternatives tables describe supply, not clinical equivalence.

Health Canada Drug Product Database (DPD), DIN 02230593. Last reviewed 2026-09-10. Nexara Health is a licensed wholesaler and supplies licensed entities only; consumer orders are routed to a partner pharmacy.